AMCP submits comments to FDA on Hatch-Waxman reform advocating for the prohibition of strategies that unnecessarily delay the entry of generic medications into the marketplace for reasons other than safety and efficacy
AMCP submits comments to FDA on Hatch-Waxman reform advocating for the prohibition of strategies that unnecessarily delay the entry of generic medications into the marketplace for reasons other than safety and efficacy